{"name":"Advenchen Laboratories, LLC","slug":"advenchen-laboratories-llc","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Cardiovascular","slug":"cardiovascular","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Digoxin (0.25mg)","genericName":"Digoxin (0.25mg)","slug":"digoxin-0-25mg","indication":"Heart failure with reduced ejection fraction","status":"phase_3"}]}],"pipeline":[{"name":"Digoxin (0.25mg)","genericName":"Digoxin (0.25mg)","slug":"digoxin-0-25mg","phase":"phase_3","mechanism":"Digoxin inhibits the Na+/K+-ATPase pump, increasing intracellular calcium and enhancing cardiac contractility while slowing atrioventricular node conduction.","indications":["Heart failure with reduced ejection fraction","Atrial fibrillation with rapid ventricular response"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMihgJBVV95cUxNYmVyVlB4UG1ZUXhpb2dDRVdwQnp4UjZ4WEc1RVBnTzQ1WktIZmVFYU5xcE1oR1NHQi1DbXU0dE50dnUxY3hSbTVzVEdDRHljdFZMdVJlLXNDY3VhWXgzVjczNUx0VFM1ZHJCSnM0Vm5wYVZaRG5zRExIQm9EZjBGSHhnd2NkV0d3OEF5UzlEZFRpZzNGQlVzWjctVzYtZWhGa0dsNVVTcUFJUUZTdTY5aUNTUlhDSXZPYTV2WDUyM2xtOHlCbF9VeWdvRmgzSGtxbkdZamZzaFkxYU1nekFhd1BpX2ZHRkctOWpjTFhHWkd2TVRzSkR1cWRvU2ZEYnVuMmtxNXV3?oc=5","date":"2026-03-30","type":"trial","source":"Barchart.com","summary":"Gastrointestinal Stromal Tumors Clinical Trial Pipeline Expands as 25+ Companies Driving Innovation in the Therapeutics | DelveInsight - Barchart.com","headline":"Gastrointestinal Stromal Tumors Clinical Trial Pipeline Expands as 25+ Companies Driving Innovation in the Therapeutics ","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi3wFBVV95cUxNdng2bURQeEpQU1c4Z1VrZUFPSTVIOVNjVE9KUld2UFpSSEtaYkNLakViejJnTjFMNDZnQXFsaVdmTlp2TjAtMlU5aDA0WFljV0MxblhDcWdiZnlicERXTTZUdFRSWEdVYXlXcWd1S1V1MUw0ckFyVVp3QVVXUW9XSUpPazh4S2V0WGZDTlJiZWxzRERyYTllRUp0VDFLcnUtMnVMZGdWcGJDNkFoS1BsYU51VUJnU3B6Tl9RVnBwd0RZSVhyVGFVR05kRFFabVFtQU4yZ0RmRDAwREdlcWk0?oc=5","date":"2026-03-26","type":"pipeline","source":"Barchart.com","summary":"PI3K Inhibitor Treatment Pipeline Shows Strong Momentum as 20+ Pharma Companies in the Race | DelveInsight - Barchart.com","headline":"PI3K Inhibitor Treatment Pipeline Shows Strong Momentum as 20+ Pharma Companies in the Race | DelveInsight","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi_wFBVV95cUxPNjJBXzE5X0pwT3BfalJmLUZ4djRzczM5UEFnWldGSzl6Mkl3Rl81M09wODBaaFBmczNDNkxMWS1Ib05SeV9hUS0zLVZGc05LcnJHYk5OMk9MS3RGVDBKMVR1M1ZhRjdyMVdsbloxYzVnaTJiVlZaaDlfVThseFpSVDRnelUwLVUtUERIVEo5ZUV5b1daclQ2T2d0eFlkWWJaY2dSNWNIcWJsTmdvMDlzdUFacTZ5czczX19CX1dvbS13OV9wZ0lxOHBNWXYtc0RhWXNQNjlBdGpzaGZ4eklUQmNIX3Q3ZXN2ejczZzNlSHo4YWg5aVcyeDBYUjktdlE?oc=5","date":"2025-10-20","type":"pipeline","source":"prnewswire.com","summary":"Liposarcoma Market Set to Grow at a Steady CAGR by 2034 Amid Increasing Clinical Research Activities | DelveInsight - prnewswire.com","headline":"Liposarcoma Market Set to Grow at a Steady CAGR by 2034 Amid Increasing Clinical Research Activities | DelveInsight","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqgJBVV95cUxOYXM2QTdfbmJwVURFUnBPWXp0REUyblpQNXVXQ1NrY2IwVjdlQzFGaGhmcmZiclZoU0RBQzU0YV9UNmltUVRMX0ZHMEFhU3FzemVjQ1FrcmZ6YllSdmpqM3ROa19fQU1HTzc3SHBBQmFNYXgwaEdPZUNSX3I3RHd0N040MHRiSG95THF6M2FtMDhwQUxSNHhWQWpJNDZvdW9tLU5fT2k3UmQ2MC1kYXZ4ZkVPcC1lMlhHWlhWaEtKOG9HYjFTeFJvdzk2djd1RjVTQUR3LU1sclEwSzJiYUFBN3F3aG1tbXkzckFiT2xzV2VfQjJEY2tNRy02dEp3elFYQmg5Njk0ZThfMEs4eEhYaDhXMFRqVWd2VXdjMXZER0JQVXVVY0VrNGpn?oc=5","date":"2025-07-30","type":"pipeline","source":"prnewswire.com","summary":"Osteosarcoma Market on the Rise in the 7MM During the Forecast Period (2025-2034) with Novel Therapeutics and Technological Innovations | DelveInsight - prnewswire.com","headline":"Osteosarcoma Market on the Rise in the 7MM During the Forecast Period (2025-2034) with Novel Therapeutics and Technologi","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirAJBVV95cUxOVE85QlhZaUcxdWVBeHZGaHZxcWJ6N21naFV1cTFROExZRS1nRjRadnQwZWpfMlVJLTl0aW94VExXUkxDSDFfZEY5V01WLVVDSjJTS1lvbUJaWnBtQ2FDQXphODFXeEtUdjJRVHllUEp3WlpYQlluQWpuWlE3TWZmYnNJT0tSazY2OVprRS1BTV9VQzdQQnQ5d1RRVXpaSnJ4RjJRaXhoNkYzbURUMEFWeHZJZmhsRGdRUng4djFZUTNXVWd4b19fUDJxNnhkeTNWQ09kaVZIVk1zUTNNQm5DYTV6YzFnNFFhTnVrTEhjMmFwQzZXdjNTMHhSRTdsRkxhaVZhcXlZbm5YRU9uSHljc2VIQmNBWGpMSjlnb09WcTgtU0x2c0FUV0Y3aUc?oc=5","date":"2025-05-08","type":"pipeline","source":"GlobeNewswire","summary":"High- and Low-Grade Serous Ovarian Cancer Market is - GlobeNewswire","headline":"High- and Low-Grade Serous Ovarian Cancer Market is","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinwJBVV95cUxOdVlhOFhDYnpBRGh4WlhFWG93ZHdmak5FZDVRVC1qWER1YlFhbnQ5TThBM0Y5ZjJaaExucGI2LVNsSmRUMDQ3cVBHT211N1JHVXNBRklDUTR1VjdITWkxSTA5OXNTMkZ2S3hnVDBMNHJYamp2Ri1UcHhBRlBLUWNxLXFMeHRlXzFpOXpkRzF4NlZWYlBGS0xqaGlHSlMzMkRFcG1tRjd4aU5sOE5TUWJvdklNd0F5YmZIMU91Tng5X0F3UlJESVI1M0tDaUFid2c1MjlhMlFiTHNGaUViTkN3b01pM2J4cndGY0NueG9VTTl0bGtmWF9KcEpZOVlodHZQWE5FbW1aNDBzTTNZTVNWTWpWZjhVM00zcHZIUV9sTQ?oc=5","date":"2025-01-14","type":"trial","source":"prnewswire.com","summary":"Non-Small Cell Lung Cancer Clinical Trial Pipeline Boom as Over 100 Companies Leading the Charge in Research and Development | DelveInsight - prnewswire.com","headline":"Non-Small Cell Lung Cancer Clinical Trial Pipeline Boom as Over 100 Companies Leading the Charge in Research and Develop","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi7AFBVV95cUxQVzdMMWJULWVjYzhsdExRZmRRWHFHTFB3U1RGd3JtQWVXSEt1bWdWbElFRE5BXzlYZ1VZYWxDYmJGaTR5Q2J3STVRV2piTHluNmVNN2N4MUVJWTMyWlFNa2tSeUgzeFVCR0pvb0FPTWJHMVBQaU1iandhalJ1UGJhT3Y5X3EzbU5VcHBXNGVzNVF5RnFUejZpNHp2d0FTcVlQeXBDRE5wS21xVkgxVmg1eTY0ODZIeUU1Y2NVM1hyZFNlLUxqUVBQcDBzY21tNDJwNGtQNWMtSGV5WVc1Tkl0Y1hUczNuQUIxMnVMTA?oc=5","date":"2024-10-07","type":"pipeline","source":"GlobeNewswire","summary":"Innovative B7-H3 Inhibitors Set to Transform Cancer Treatment Landscape | DelveInsight - GlobeNewswire","headline":"Innovative B7-H3 Inhibitors Set to Transform Cancer Treatment Landscape | DelveInsight","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilgFBVV95cUxORHo3M2p3MHhUWW44b2l4WU95VWc0eGJERzFkSWEzempiUDgtbjA0bGk5cmp3U21DdVJMVFdtUVN4VGs2U2Z5aURnUVFhVUZ0U2l5TUZJQ29fZUwtX0d0d05xc051MDZFV2cwa3c4MmZOQ0J4WWZ4UWlYYlZCTFNPVWMzS1FwWm1HQXMyTDBGNGR2QUZnZ2c?oc=5","date":"2024-05-17","type":"regulatory","source":"Fierce Pharma","summary":"FDA snubs another China-made PD-1 with rejection of Elevar, Hengrui's liver cancer combo - Fierce Pharma","headline":"FDA snubs another China-made PD-1 with rejection of Elevar, Hengrui's liver cancer combo","sentiment":"negative"}],"patents":[],"drugCount":1,"phaseCounts":{"phase_3":1},"enrichmentLevel":0,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}